Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advanced Bionics

Executive Summary

Implantable electrostimulation devices.

Business:Implantable electrostimulation devices
Contact:Jeffrey Greiner, President & COO
Address:12740 San Fernando Rd., Sylmar, CA 91342
Phone:(818) 362-7588
Founded: January 1994

An estimated two million Americans who are profoundly deaf cannot be helped with a hearing aid, which merely amplifies sound, because they suffer from sensorineural deafness (an absence of hair cells in the inner ear which convert sound waves to electrical signals). Cochlear implants can help this population by bypassing hair cells to send electrical signals directly to the auditory nerve. Advanced Bionics’ Clarion, the only US-made implantable cochlear device, is sold in the US and 28 countries. It consists of an implant that has 16 electrodes within the cochlea and an external speech processor box connected to a behind-the-ear headpiece containing an implanted receiver. Clarionsends sound waves directly to the system’s speech processor which converts them to electrical impulses that directly stimulate the auditory nerve. FDA-approved for adults in March 1996, Clarion has enabled over 60% of the post-lingually deaf adults who have tested the device to communicate without reading lips and to use the telephone.

In an $85 million worldwide market, Clarioncompetes with cochlear implants made by Australian-based Cochlear Ltd. and Med-EL, an Austrian company with a device about to begin clinical trials in the US.

With an R&D team numbering over 25, long-term growth plans include other neuro-stimulation products in the areas of female incontinence and sleep disorders.

The 150-employee company, originally an R&D arm of MiniMed Technologies ( microinfusion insulin pumps) was funded by investors who have in the past invested in ventures of the Chairman, CEO and founder, Alfred Mann. Mr. Mann, formerly CEO at Pacesetter Systems, is Pres. & CEO of Minimed Inc. Jeffrey Greiner, President and COO, was previously at Siemens-Pacesetter and MiniMed. William Van Harrison, formerly with Acoustic Imaging Corp., is VP of R&D.—MR

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV000298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel